Grid Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Grid Therapeutics's estimated annual revenue is currently $775k per year.
- Grid Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Grid Therapeutics has 5 Employees.
- Grid Therapeutics grew their employee count by 0% last year.
Grid Therapeutics's People
| Name | Title | Email/Phone |
|---|
Grid Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $11.2M | 72 | -13% | N/A | N/A |
#2 | $5099.8M | 32902 | -4% | N/A | N/A |
#3 | $1.7M | 11 | 0% | N/A | N/A |
#4 | $0.6M | 4 | -56% | N/A | N/A |
#5 | $0.9M | 11 | -39% | N/A | N/A |
#6 | $1.7M | 11 | 10% | N/A | N/A |
#7 | $0.6M | 4 | -33% | N/A | N/A |
#8 | $4.8M | 31 | -6% | N/A | N/A |
#9 | $6.4M | 41 | 3% | N/A | N/A |
#10 | $4.2M | 27 | -18% | N/A | N/A |
What Is Grid Therapeutics?
Grid Therapeutics is a biotech company based on the innovative science first developed by Edward F. Patz, Jr. MD and his team of scientists at Duke University Medical Center. Located in Durham, North Carolina, Grid is developing the first human derived targeted immunotherapy for cancer. The antibody was discovered in exceptional outcome early stage lung cancer patients who did not progress to develop metastasis. The antibody was isolated from patient’s B-cells using state of the art molecular genomic techniques. “GT103â€, the company’s lead asset, is currently enrolling the first-in-man Phase 1 clinical trial in refractory NSCLC patients.
keywords:N/A
N/A
Total Funding
5
Number of Employees
$775k
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Durham
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.8M | 5 | 0% | N/A |
#2 | $0.7M | 5 | -78% | N/A |
#3 | $0.8M | 5 | -29% | N/A |
#4 | N/A | 5 | -29% | N/A |
#5 | $0.5M | 5 | 0% | N/A |